Premium
Five‐year survival of patients with oral cancer and its association with antibody to herpes simplex virus
Author(s) -
Shillitoe Edward J.,
Greenspan Deborah,
Greenspan John S.,
Silverman Sol
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19861115)58:10<2256::aid-cncr2820581016>3.0.co;2-g
Subject(s) - medicine , antibody , herpes simplex virus , virus , immunology , cancer , cytomegalovirus , gastroenterology , virology , herpesviridae , viral disease
Levels of antibody to herpes simplex virus type 1 (HSV‐1) were measured in 70 patients with untreated squamous cell carcinoma of the mouth. After treatment the actuarial survival was determined at quarterly intervals for 5 years and was found to be associated with the pretreatment level of antibody to the virus. Patients with levels of IgM antibody to HSV‐1 which were above the median level had a 5‐year survival of only 56% whereas those with levels below the median had a higher survival of 72%. Patients with no detectable IgM antibody to HSV‐1 had a 5‐year survival of 81%. The reverse was seen with IgG antibody to HSV‐1. Patients with higher than the median level of IgG antibody had a 5‐year survival of 73%, whereas those with IgG antibody below the median had a 5‐year survival of 56%. No relationship was seen between survival and levels of IgA antibody to HSV‐1, or between survival and antibody of any class to cytomegalovirus. The data are consistent with the reported association between oral cancer and HSV‐1.